Clinically proven prescription weight loss1,2

See the results over time and help your patients succeed

Now $98 Flat Pricing Access. All Doses. §

Qsymia is the only once-daily combination pill that along with diet and exercise is proven to significantly reduce weight1-5

Clinically proven results in 56-week Qsymia studies1,2

See the average results of patients who were participating in the studies at the 12, 28 and 56-week time points. These are important time points to help you evaluate your patients’ status and assess their treatment plan.1,2‡

 

The results presented here are from the combined studies supporting FDA approval of Qsymia. Qsymia was studied in 2 large trials that involved 3754 patients whose BMI was 27 kg/m2 or greater. For the subjects in the 2 trials the average baseline weight was 256 lbs and 227 lbs, and the average baseline waist circumference was 47 inches and 45 inches. Patients were randomized to placebo, phentermine 3.75 mg/topiramate 23 mg, phentermine 7.5 mg/topiramate 46 mg, or phentermine 15 mg/topiramate 92 mg. In these trials, it was recommended that patients eat a well-balanced diet and reduce their caloric intake by 500 kcal/day. Your patients’ results may vary depending on their weight, BMI, diet, activity level, dose of Qsymia, and other factors.

The chart presents data for patients who completed treatment at each time point. Some patients left the study or stopped taking Qsymia prior to completing the full 56 weeks. The drop off rate for placebo was 47% (687/1477), recommended dose was 31% (150/488) and top dose was 38% (561/1479). The most common reasons (>2% of patients) were: adverse events, patients lost to follow up, patients who withdrew consent, or lack of efficacy.

Analysis of all patients (including those who dropped off) results in slightly smaller reductions in weight and waist circumference. Weight loss in all patients was 4.7 lbs, 14.1 lbs, and 17.2 lbs with placebo, Qsymia 7.5 mg/46 mg, and Qsymia 15 mg/92 mg, respectively, at 12 weeks; 5.4 lbs, 19.5 lbs, and 24.3 lbs with placebo, Qsymia 7.5 mg/46 mg, and Qsymia 15 mg/92 mg, respectively, at 28 weeks; and 3.8 lbs, 19.5 lbs, and 24.7 lbs with placebo, Qsymia 7.5 mg/46 mg, and Qsymia 15 mg/92 mg, respectively, at 56 weeks. The reduction in waist circumference was 1.1 inches, 2.2 inches, and 2.5 inches with placebo, Qsymia 7.5 mg/46 mg, and Qsymia 15 mg/92 mg, respectively, at 12 weeks; 1.3 inches, 3.2 inches, and 3.7 inches with placebo, Qsymia 7.5 mg/46 mg, and Qsymia 15 mg/92 mg, respectively, at 28 weeks; and 1.2 inches, 3.4 inches, and 4.0 inches with placebo, Qsymia 7.5 mg/46 mg, and Qsymia 15 mg/92 mg, respectively, at 56 weeks.

The titration schedule for the studies was faster than what is recommended in the Qsymia package insert. Subjects took the 3.75 mg/23 mg strength for one week, then the 7.5 mg/46 mg strength for one week (unless randomized to this arm); then the 11.25 mg/69 mg strength for one week, followed by the 15 mg/92 mg strength.1,2

Important Safety Information

Qsymia is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity or idiosyncrasy to sympathomimetic amines, topiramate, or any of the inactive ingredients in Qsymia.

VIEW ALL +
Online ordering with convenient home delivery.
You pay only $98 across all doses.§
Exclusively priced for cash patients. Additional shipping and handling costs will apply.
LEARN MORE
LEARN MORE AND SAVE